chemotherapy with a high rate of febrile neutropenia. 9 Table 2 displays the benefits and potential risks of parenteral iron administration reported in a variety of patient populations or studied in animal models. Because these risks have not specifically
Search Results
Jeffrey A. Gilreath, David D. Stenehjem, and George M. Rodgers
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022
Featured Updates to the NCCN Guidelines
Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. de Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan Madanat, Lori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, and Cindy Hochstetler
14.8 months (95% CI, 12.9 months–not estimable), respectively. 17 The most frequent grade ≥3 adverse events were neutropenia (51%), febrile neutropenia (46%), and thrombocytopenia (30%). In a study exploring venetoclax as a salvage agent alone or in
Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross
), and 25% of all patients treated with chemotherapy would receive granulocyte colony-stimulating factor (G-CSF) pegfilgrastim (on average 2 cycles) for the secondary prevention of febrile neutropenia. 18 For patients who did not receive ODX testing, we
Jaffer A. Ajani, Thomas A. D'Amico, Khaldoun Almhanna, David J. Bentrem, Joseph Chao, Prajnan Das, Crystal S. Denlinger, Paul Fanta, Farhood Farjah, Charles S. Fuchs, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, Stephen Leong, Catherine Linn, A. Craig Lockhart, Quan P. Ly, Mary F. Mulcahy, Mark B. Orringer, Kyle A. Perry, George A. Poultsides, Walter J. Scott, Vivian E. Strong, Mary Kay Washington, Benny Weksler, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian, and Hema Sundar
oxaliplatin (37%) or docetaxel, oxaliplatin, and capecitabine (38%). Febrile neutropenia was reported in only 2% of patients treated with docetaxel, oxaliplatin, and fluorouracil (compared with 14% and 9% for docetaxel/oxaliplatin and docetaxel, oxaliplatin
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
; febrile neutropenia rate was 4% versus 14%, and other toxicities and overall QOL were similar. Docetaxel is included as an upfront option for men with castration-naïve prostate cancer and distant metastases based on results from 2 phase 3 trials (ECOG 3805
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, OCN, Lydia Hammond, and Ndiya Ogba
and control groups were febrile neutropenia (68.0% vs 70.9%), pneumonia (19.6% vs 14.6%), and hypoxia (13.1% vs 15.2%). 40 Other Regimens for Intermediate- or Poor-Risk Cytogenetics Standard-Dose Cytarabine, Anthracycline, and Cladribine A phase III
Katy Winckworth-Prejsnar, Elizabeth A. Nardi, Lisa Korin Lentz, Jeffrey A. Crawford, C. Lyn Fitzgerald, and Robert W. Carlson
-CSF). It is approved for all indications of filgrastim to treat patients with (1) nonmyeloid malignancy receiving myelosuppressive chemotherapy with an intermediate- or high-risk of febrile neutropenia; (2) acute myeloid leukemia receiving induction or
Armin Rashidi and Nancy L. Bartlett
% and 96%, respectively. The corresponding rates for 3-year OS were 92% and 100%, respectively. The incidence of febrile neutropenia was 20% and 8% in the 2 cohorts, respectively. The phase I regimen served as the basis for the currently active phase III
Sumanta K. Pal, Matthew I. Milowsky, and Elizabeth R. Plimack
). However, in the eligible study population, a 3.2-month improvement in OS was observed with PGC (HR, 0.82; P =.03). Despite this improvement, the incidence of thrombocytopenia, bleeding, and febrile neutropenia were all greater with the 3-drug combination
Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth
-EPOCH-R at 24 academic centers, 3-year EFS was 86% (95% CI, 80.3%–91.5%). 27 Although pediatric EFS rates are less than those seen in adults, the DA-EPOCH-R regimen (without radiation) has fewer acute toxicities, including less stomatitis, enteritis, febrile
